Raymond James analyst Dane Leone maintained a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) on Thursday, setting a price target of $25, which is approximately 23.09% above the present share price of $20.31.
Leone expects Ocular Therapeutix to post earnings per share (EPS) of -$0.19 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Ocular Therapeutix, with an average price target of $27.6.
The analysts price targets range from a high of $30 to a low of $25.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $5.88 million and a net profit of -$14.01 million. The company's market cap is $1.39 billion.
According to TipRanks.com, Raymond James analyst Dane Leone is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.7% and a 65.03% success rate.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.